Navigation Links
TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
Date:9/2/2008

NATICK, Mass. and Munich, Germany, Sept. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive one-year results from the European and Intercontinental launch phases of its global TAXUS OLYMPIA registry, the world's largest post-approval, prospective registry for a single drug-eluting stent (DES). OLYMPIA is designed to analyze real-world clinical outcomes data for Boston Scientific's second-generation TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System in the treatment of patients with coronary artery disease. Results from the 22,000-patient study were presented by Oscar Mendiz, M.D., at the European Society of Cardiology Congress in Munich, Germany.

The TAXUS OLYMPIA registry employs a consecutive enrollment process and consists of diverse and high-risk patient populations, reflecting real-world usage patterns found in everyday clinical practice. One-year data were collected for a total of 22,345 patients to date in 57 countries. A large majority of patients (75%) were considered "expanded use" cases consisting of complex lesions or complex clinical characteristics. The overall OLYMPIA population in these two phases included patients with multivessel disease (56.5%), prior PCI (27.9%), prior myocardial infarction (MI) (34.1%), multiple stents (32.3%), and medically treated diabetes (27.0%).

The one-year results demonstrated a low overall 3.8 percent rate of TAXUS Liberte stent-related composite cardiac events, including cardiac death (1.2%), MI (0.8%), and re-intervention (TLR) (2.5%). The definite stent thrombosis rate was 0.8 percent after one year, which is consistent with safety data from other DES registries. In the more complex expanded use patient population, the rates
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SPIRIT III Results Reaffirm Strong Performance of Boston Scientific PROMUS(TM) and TAXUS(R) Express(R) Stents
2. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
3. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
4. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
5. OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) has Lower MACE Rate than TAXUS(R) and CYPHER(R) Stents in Clinical Trial
6. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
7. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
8. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
9. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
10. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 InformEx, ... buyers and sellers of high-value chemistry, will hold the 30 ... Miami Beach Convention Center from January 21-24. ... than 3,500 attendees from top pharmaceutical, fine chemical and specialty ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... REDWOOD CITY, Calif., July 14, 2011 Codexis, Inc. (Nasdaq: ... in the 13th Annual Pacific Crest Global Technology Leadership Forum, ... Robert Lawson, Senior Vice President and Chief Financial Officer, will ... Biofuels and Renewable Chemicals," scheduled for August 8 at 12:30 ...
... ACCESS PHARMACEUTICALS, INC. (OTCBB: ... to develop treatments in areas of oncology, cancer supportive ... oral mucositis, MuGard , has been added to ... is now available with standard pharmacy benefit copayment.  Placement ...
Cached Medicine Technology:Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 2Access Pharmaceuticals MuGard Added to CVS Caremark's Pharmacy Benefit Network 3
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... the most important organs in the human body. Its ... properly this is its synthesis function and ... this is its detoxification function. Lack of exercise and ... the liver. The resulting diseased cells can lead to ... failure. According to the German Liver Foundation, over five ...
(Date:7/9/2014)... prescription labels handed out by pharmacists may be ... medication, according to new research by the University ... the Blind)., The study, published recently in the ... on prescription medications dispensed by pharmacies do not ... By simply following recommended guidelines for font size, ...
(Date:7/9/2014)... , , , ... , , , , ... downrange from the firer and approximately 30cm from the bullet... , , ... , , , , ... , , , , , , University of Southampton researchers, with ...
(Date:7/9/2014)... The occurrence of allergic diseases has risen dramatically in ... are less exposed to microorganisms and have fewer infections ... system. , A study by researchers at Sahlgrenska Academy, ... three to examine maturation of the immune system in ... in rural areas of the Vstra Gtaland Region, half ...
Breaking Medicine News(10 mins):Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7
... March 17 JumpStart Inc. , ... progress of high growth early-stage businesses, and Case ... and technology validation fund at Case Western Reserve ... in Neuros Medical, Inc. , a Cleveland, OH ...
... Research Group, Inc. has been covering the biologics market ... series which are syndicated primary research reports ... and Rheumatologists. The company is now expanding these ... reports which aim to compare self-reported treatment patterns ...
... in Mexico for Minimally Invasive Treatment for Prostate ... elite urologistsCHARLOTTE, N.C., March 16 Mexico HIFU ... international entities of USHIFU, a global leader in ... focused ultrasound (HIFU) technologies, will host the very ...
... 16 Star Scientific, Inc. (Nasdaq: STSI ... with the Securities and Exchange Commission. The company reported ... unchanged from net sales for 2007. However, volume sales ... and Stonewall(R), increased 7.8% in 2008 compared to 2007. ...
... March 16 /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: ... that the Company is calling its $12.4 million of ... Notes"). In addition, the,Company announced the completion of ... Exchanged $1.0 million in principal amount 10.0% senior secured, ...
... in St. Louis and Johns Hopkins University, in partnership with Experience Corps, has showed that people over 55 ... Click here for more information. , , ... , , , , ... , , , ...
Cached Medicine News:Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 2Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 3Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 4Health News:JumpStart and Case Technology Ventures Invest in Neuros Medical 5Health News:BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis 2Health News:High Intensity Focused Ultrasound Physician Training Seminar in Mexico City 2Health News:Star Scientific Files Annual Financial Report 2Health News:Star Scientific Files Annual Financial Report 3Health News:Star Scientific Files Annual Financial Report 4Health News:BMP Sunstone Exchanges and Calls Outstanding Notes Due May 2009 2Health News:Researchers find sustained improvement in health in Experience Corps tutors over 55 2Health News:Researchers find sustained improvement in health in Experience Corps tutors over 55 3Health News:Researchers find sustained improvement in health in Experience Corps tutors over 55 4
... PS+ lead series are endocardial ... the best characteristics of polyurethane ... polyurethane outer insulation provides a ... lubricity while the silicone inner ...
The Vitatron Slimtine S lead series are endocardial leads with an excellent history of reliability and optimal handling en pacing performance....
Unipolar Atrial "J" Lead...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: